Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid

Caobelli, Federico; Chiaravalloti, Agostino; Evangelista, Laura; Saladini, Giorgio; Schillaci, Orazio; Vadrucci, Manuela; Scalorbi, Federica; Donner, Davide; Alongi, Pierpaolo

doi:10.1007/s12149-017-1213-0

Cited by 19 publications

(43 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our institution, 18 F-DOPA-PET/CT is performed for whole-body tumour staging in MTC since numerous studies demonstrated superiority to 18 F-FDG hybrid imaging [6, 8–10, 35]. The detection of liver metastases in MTC patients, however, is difficult due to the typically small size with correspondingly low 18 F-DOPA uptake or size below the spatial resolution of PET imaging.…”

Section: Discussionmentioning

confidence: 99%

The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma

et al. 2019

View full text Add to dashboard Cite

BackgroundA high proportion of patients with advanced stages of medullary thyroid carcinoma (MTC) present with liver metastasis metastases. The aim of our study was to investigate the added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in MTC.MethodsThirty-six patients (14 female, median age 55 years) with histologically confirmed MTC undergoing gadoxetic acid-enhanced liver MRI within 1 month of matching contrast-enhanced 18F-DOPA-PET/CT between 2010 and 2016 were selected for this IRB-approved retrospective study. 18F-DOPA-PET/CT and multiparametric MRI data sets were read consecutively and liver lesions were categorised on a 5-point Likert scale (1–definitely benign; 2–probably benign; 3–intermediate risk for metastasis; 4–probably metastasis; 5–definitely metastasis). It was noted if gadoxetic acid-enhanced MRI detected additional, 18F-DOPA-PET/CT-occult metastases (category 5) or if gadoxetic acid-enhanced MRI allowed for a definite classification (categories 1 and 5) of lesions for which 18F-DOPA-PET/CT remained inconclusive (categories 2–4). Follow-up PET/CT and MRI examinations were used as a reference standard.ResultsA total of 207 liver lesions (18F-DOPA-PET/CT 149, MRI 207; 152 metastases, 37 benign cysts, 18 hemangiomas) were analysed. Fifty-eight additional lesions were detected by MRI, of which 54 were metastases (median diameter 0.5 cm [interquartile range 0.4–0.7 cm]) occult on 18F-DOPA-PET/CT. MRI allowed for a definite lesion classification (categories 1 and 5) in 92% (190/207) whereas 18F-DOPA-PET/CT allowed for a definite lesion classification in 76% (113/149). MRI lead to a change in lesion categorisation in 14% (21/149).ConclusionGadoxetic acid-enhanced MRI allows for a more precise liver staging in MTC patients compared to 18F-DOPA-PET/CT alone, particularly for 18F-DOPA-negative metastases and lesions < 1 cm.

show abstract

Section: Discussionmentioning

confidence: 99%

The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Due to its greater spatial resolution, lower radiation dose and improved diagnostic accuracy as well as patients convenience, 68 Gallium-SSTR-PET has replaced SSTR scintigraphy as the standard imaging technique for NEN staging [8•].…”

Section: Gallium-sstr Imagingmentioning

confidence: 99%

“…Using the chelator DOTA (tetra-zacyclododecane-tetraacetic acid), the radiometal 68 Gallium (Ga) is conjugated with an SSA peptide. While 68 Ga-DOTATOC and -NOC use octreotide (Tyr-3/1-Nal3) with affinity for the SSTR subtypes 2, 3, and 5, 68 Ga -DOTATATE uses octreotate which has an enhanced affinity for the SSTR subtype 2 [36]. Clinically, there is no real difference between 68 Ga-DOTATOCand 68 Ga-DOTATATE-based PET imaging [37,38], their respective use often depends on the availability of the centers.…”

Section: Gallium-sstr Imagingmentioning

confidence: 99%

“…While 68 Ga-DOTATOC and -NOC use octreotide (Tyr-3/1-Nal3) with affinity for the SSTR subtypes 2, 3, and 5, 68 Ga -DOTATATE uses octreotate which has an enhanced affinity for the SSTR subtype 2 [36]. Clinically, there is no real difference between 68 Ga-DOTATOCand 68 Ga-DOTATATE-based PET imaging [37,38], their respective use often depends on the availability of the centers. The dosage for PET imaging is 2 MBq of 68 Ga-DOTA-SSA per kg body weight (up to 200 MBq) i.v.…”

Section: Gallium-sstr Imagingmentioning

confidence: 99%

“…Clinically, there is no real difference between 68 Ga-DOTATOCand 68 Ga-DOTATATE-based PET imaging [37,38], their respective use often depends on the availability of the centers. The dosage for PET imaging is 2 MBq of 68 Ga-DOTA-SSA per kg body weight (up to 200 MBq) i.v. and a PET-CT is run 60 min after injection.…”

Section: Gallium-sstr Imagingmentioning

confidence: 99%

See 2 more Smart Citations

New Directions in Imaging Neuroendocrine Neoplasms

et al. 2021

View full text Add to dashboard Cite

Purpose of Review Accurate imaging is crucial for correct diagnosis, staging, and therapy of neuroendocrine neoplasms (NENs). The search for the optimal imaging technique has triggered rapid development in the field. This review aims at giving an overview on contemporary imaging methods and providing an outlook on current progresses. Recent Findings The discovery of molecular targets due to the overexpression of specific peptide hormone receptors on the NEN’s surface has triggered the development of multiple radionuclide imaging modalities. In addition to the established imaging technique of targeting somatostatin receptors, several alternative radioligands have been developed. Targeting the glucagon-like peptide-1 receptor by exendin-4 has a high sensitivity in localizing insulinomas. For dedifferentiated NENs, new molecular targets such as the C-X-C motif chemokine-receptor-4 have been evaluated. Other new targets involve the fibroblast activation protein and the cholecystokinin-2 receptors, where the ligand minigastrin opens new possibilities for the management of medullary thyroid carcinoma. Summary Molecular imaging is an emerging field that improves the management of NENs.

show abstract

18f-Dopa

Calabria¹,

Schillaci

2019

Radiopharmaceuticals

View full text Add to dashboard Cite

Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid

Abstract: F-DOPA PET/CT scan has an important prognostic value in predicting disease progression and mortality rate.

Cited by 19 publications

References 21 publications

The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma

The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma

New Directions in Imaging Neuroendocrine Neoplasms

18f-Dopa

Contact Info

Product

Resources

About